|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
ChemGenex Pharmaceuticals Limited (CXS.AX) Licenses Targeted Platinum IV Compound From The University of Texas M. D. Anderson Cancer Center
10/19/2005 5:12:40 PM
MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--Feb. 9, 2005--
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that it has licensed a novel platinum (IV) agent from The University of Texas M. D. Anderson Cancer Center in Houston, Texas, one of the world's most respected cancer research and treatment institutions. The patented molecule, now called CXS299, is a platinum (IV) anti-cancer agent invented by Zahid H. Siddik, Ph.D. and Abdul R. Khokhar, Ph.D., professors in the Department of Experimental Therapeutics at M. D. Anderson Cancer Center. CXS299 is active against cancer cells resistant to approved platinum-based therapies and possesses unique properties that may allow physicians to target patients who are most likely to benefit from therapy.
|
|
|
|
|
|
|
|
|
|
|